Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Pick a track — progress rings update as you complete lessons.
7 lessons
8mGHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.
8mMost people fighting hair loss default to minoxidil. But a 2022 clinical trial showed a 0.5% GHK-Cu serum increased hair count by 22% over 16 weeks — beating 3% minoxidil. And GHK-Cu doesn't just grow hair. It works at the genomic level.
7mOn April 15, 2026, the FDA announced it will remove injectable GHK-Cu from Category 2 — the list that blocked compounding pharmacies from producing it. This is a major regulatory shift for one of the most studied copper peptides in longevity research.
9mGHK-Cu has long been known for its skin and healing benefits. A fresh April 2026 preprint adds a surprising new dimension — cognitive aging reversal in mouse models via BDNF upregulation and neuroinflammation suppression.
10mMost people know GHK-Cu for skin and wound healing. What they don't know: it's one of the most potent epigenetic regulators ever studied, influencing over 4,000 human genes — many tied directly to aging, inflammation, and tissue repair.
9mA 2026 Phase 2 clinical trial confirms GHK-Cu achieves 25% faster wound closure and tissue regeneration versus control. Discover how this naturally occurring copper peptide triggers stem cell activity, collagen synthesis, and anti-inflammatory cascades.
7mGHK-Cu is one of the most researched anti-aging peptides available. Here's a practical dosing guide covering protocols, cycle length, stacking, and what to realistically expect.
Also available at /blog for legacy links.